Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
作者信息
Fung J J, Todo S, Jain A, McCauley J, Alessiani M, Scotti C, Starzl T E
机构信息
Department of Surgery, University of Pittsburgh School of Medicine, PA.
出版信息
Transplant Proc. 1990 Feb;22(1):6-12.
Abstract
摘要
相似文献
1
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.肝移植受者中因环孢素相关并发症而从环孢素转换为FK506治疗。
Transplant Proc. 1990 Feb;22(1):6-12.
2
A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates.FK506在灵长类动物原位肝移植中具有强大的免疫抑制作用。
Transplant Proc. 1990 Feb;22(1):66-71.
3
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.肝移植受者从环孢素转换为基于FK 506的免疫抑制：益处与风险。
Transplant Proc. 1991 Feb;23(1 Pt 1):14-21.
4
Current status of FK 506 in liver transplantation.FK506在肝移植中的现状。
Transplant Proc. 1991 Jun;23(3):1902-5.
5
Strategy for chronic rejection in recipient of living-related liver transplantation.活体亲属肝移植受者慢性排斥反应的策略。
Transplant Proc. 2000 Nov;32(7):2134-6. doi: 10.1016/s0041-1345(00)01603-1.
6
Pathologic observations in human allograft recipients treated with FK 506.接受FK 506治疗的人类同种异体移植受者的病理观察
Transplant Proc. 1990 Feb;22(1):25-34.
7
Successful conversion from cyclosporine to tacrolimus for immunosuppression.成功将环孢素转换为他克莫司进行免疫抑制。
Transplant Proc. 2000 Nov;32(7):2120-2. doi: 10.1016/s0041-1345(00)01597-9.
8
Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy.肝移植受者从环孢素A转换为FK506免疫抑制治疗。
Transplant Proc. 2000 Jun;32(4):709-10. doi: 10.1016/s0041-1345(00)00951-9.
9
Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage.霉酚酸酯治疗肝移植后丙型肝炎病毒再感染患者的意义：对临床病程和组织学损伤的影响。
Transplant Proc. 2002 Nov;34(7):2934-5. doi: 10.1016/s0041-1345(02)03494-2.
10
Cyclosporine A reduction and withdrawal in liver transplantation: a risk-benefit analysis.肝移植中环孢素A的减量与停用：风险效益分析
Transplant Proc. 1997 Nov;29(7):2819-21. doi: 10.1016/s0041-1345(97)00691-x.
引用本文的文献
1
Global research hotspots and trends of acute rejection after liver transplantation from 1988 to 2022: a bibliometric analysis.1988年至2022年肝移植术后急性排斥反应的全球研究热点与趋势：一项文献计量分析
Front Pharmacol. 2024 Apr 17;15:1357468. doi: 10.3389/fphar.2024.1357468. eCollection 2024.
2
The yesterday, today and tomorrow of liver transplant.肝移植的昨天、今天与明天。
Med J Armed Forces India. 2023 Nov-Dec;79(6):638-644. doi: 10.1016/j.mjafi.2023.08.012. Epub 2023 Sep 13.
3
A brief history of liver transplantation and transplant anesthesia.肝移植和移植麻醉的简史。
BMC Anesthesiol. 2022 Nov 26;22(1):363. doi: 10.1186/s12871-022-01904-1.
4
Treatment with hepatocyte transplantation in a novel mouse model of persistent liver failure.在一种新型持续性肝衰竭小鼠模型中进行肝细胞移植治疗。
Biochem Biophys Rep. 2022 Nov 16;32:101382. doi: 10.1016/j.bbrep.2022.101382. eCollection 2022 Dec.
5
FKBP Ligands-Where We Are and Where to Go?FKBP配体——我们所处的位置与前进的方向？
Front Pharmacol. 2018 Dec 5;9:1425. doi: 10.3389/fphar.2018.01425. eCollection 2018.
6
Liver transplantation: history, outcomes and perspectives.肝移植：历史、成果与展望
Einstein (Sao Paulo). 2015 Jan-Mar;13(1):149-52. doi: 10.1590/S1679-45082015RW3164.
7
Tacrolimus (FK506)-Associated Renal Pathology.他克莫司（FK506）相关的肾脏病理学。
Adv Anat Pathol. 1997 Jul;4(4):265-276. doi: 10.1097/00125480-199707000-00032.
8
Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipients.小儿肝移植受者从环孢素转换为他克莫司。
Paediatr Drugs. 2001;3(9):661-72. doi: 10.2165/00128072-200103090-00004.
9
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.他克莫司能否为初次肝移植后的慢性排斥反应提供几乎完全的预防？1048例肝移植患者的风险及预后因素分析，平均随访6年。
Liver Transpl. 2001 Jul;7(7):623-30. doi: 10.1053/jlts.2001.25364.
10
Immunosuppressive drugs in paediatric liver transplantation.儿童肝移植中的免疫抑制药物
Paediatr Drugs. 2001;3(1):43-60. doi: 10.2165/00128072-200103010-00004.
本文引用的文献
1
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION.FR 900506对人T淋巴细胞同种异体激活的体外免疫抑制作用。
Surg Res Commun. 1987;1:315-323.
2
Liver transplantation (1).肝移植(1)。
N Engl J Med. 1989 Oct 12;321(15):1014-22. doi: 10.1056/NEJM198910123211505.
3
Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.新型免疫抑制剂FK 506对大鼠异位心脏同种异体移植的影响。
Transplant Proc. 1987 Feb;19(1 Pt 2):1284-6.
4
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
5
Renal transplantation in baboons under FK 506.在使用FK506的情况下狒狒的肾移植
Surgery. 1989 Aug;106(2):444-50; discussion 450-1.
6
7
Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats.
Transplantation. 1987 Dec;44(6):734-8. doi: 10.1097/00007890-198712000-00002.
8
Studies of the effects of FK506 on renal allografting in the beagle dog.FK506对比格犬同种异体肾移植影响的研究。
Transplantation. 1987 Dec;44(6):729-33. doi: 10.1097/00007890-198712000-00001.
9
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.FK-506，一种从链霉菌中分离出的新型免疫抑制剂。II. FK-506的体外免疫抑制作用。
J Antibiot (Tokyo). 1987 Sep;40(9):1256-65. doi: 10.7164/antibiotics.40.1256.
10
FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.FK-506，一种从链霉菌中分离出的新型免疫抑制剂。I. 发酵、分离以及物理化学和生物学特性。
J Antibiot (Tokyo). 1987 Sep;40(9):1249-55. doi: 10.7164/antibiotics.40.1249.
Zotero 插件